Compare SPT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | NVCR |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.7M | 2.0B |
| IPO Year | 2019 | 2015 |
| Metric | SPT | NVCR |
|---|---|---|
| Price | $10.35 | $15.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $10.44 | ★ $27.14 |
| AVG Volume (30 Days) | 984.4K | ★ 1.0M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | $457,547,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $8.10 | $10.76 |
| Revenue Next Year | $6.01 | $10.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.72 | 8.28 |
| 52 Week Low | $4.92 | $9.82 |
| 52 Week High | $12.24 | $21.45 |
| Indicator | SPT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 36.23 |
| Support Level | $10.04 | $14.93 |
| Resistance Level | $10.56 | $18.43 |
| Average True Range (ATR) | 0.51 | 0.55 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 53.31 | 27.16 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.